US FDA Approves Tudriqev Viral Immunotherapy for Refractory Melanoma

• The FDA has approved Tudriqev, an engineered viral immunotherapy, for treatment-resistant advanced melanoma.
• Tudriqev is indicated in combination with nivolumab for adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on PD-1-blocking therapy.
• Clinical trial data showed that one in four patients responded to treatment, with responses lasting a median of nearly 14 months.
• Tudriqev is an oncolytic viral therapy based on a modified herpes simplex virus type 1 (HSV-1) that selectively targets and destroys cancer cells.

The FDA has approved Tudriqev, an engineered viral immunotherapy, as a new treatment option for patients with advanced melanoma who have exhausted other therapies. This approval marks a significant milestone in the fight against this aggressive form of skin cancer. According to Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research (CBER), clinicians have long been searching for effective treatments for patients whose cancer has stopped responding to PD-1 blocking therapy. Tudriqev's approval offers a glimmer of hope in this challenging area of oncology.

The treatment works by using a modified herpes simplex virus type 1 (HSV-1) that selectively targets and destroys cancer cells. Once inside the tumor, the virus replicates and breaks down cancer cells while triggering an immune response against the cancer. When used in combination with nivolumab, Tudriqev may help restore an anti-tumor immune response in patients whose cancer had previously stopped responding to immunotherapy.

Tudriqev's approval was supported by data from a clinical trial involving 140 adult patients with advanced melanoma who had experienced disease progression on prior anti-PD-1-based therapy. The trial showed that one in four patients responded to treatment, with responses lasting a median of nearly 14 months. This level of response is significant, as it offers clinicians a meaningful new tool for managing this challenging patient population.

The FDA's decision was also informed by input from clinical experts and patient advocates who emphasized the urgent need for effective treatments in this refractory population. As Megha Kaushal, Acting Deputy Director of the CBER Office of Therapeutic Products, noted, today's approval offers a meaningful new path forward for patients with advanced melanoma who have exhausted immunotherapy options.

Tudriqev's approval has significant implications for patients with advanced melanoma who have run out of other treatment options. According to the FDA, this population faces a devastating prognosis and limited treatment choices. Tudriqev offers a new hope for these patients, providing a meaningful new tool for clinicians to manage their care.

The approval also underscores the importance of continued investment in cancer research and development of innovative therapies like oncolytic viral therapy. As the FDA noted, today's milestone gives oncologists a new tool – and more patients a fighting chance.

Lawyers advising clients with advanced melanoma may want to watch for the potential use of Tudriqev as a new treatment option, especially in cases where immunotherapy has stopped working.

Source: Original reporting via U.S. Food and Drug Administration